Lipopolysaccharide of Burkholderia cepacia complex.
暂无分享,去创建一个
J. Goldberg | Arlene D Vinion-Dubiel | Joanna B Goldberg | Arlene D. Vinion-Dubiel | A. Vinion-Dubiel
[1] S. Cérantola,et al. Structural elucidation of two polysaccharides present in the lipopolysaccharide of a clinical isolate of Burkholderia cepacia. , 1997, European journal of biochemistry.
[2] J. H. Bowers,et al. Epidemiology of Pythium damping-off and Aphanomyces root rot of peas after seed treatment with bacterial agents for biological control. , 1993 .
[3] T. Beveridge,et al. Colonial Morphology of Burkholderia cepacia Complex Genomovar III: Implications in Exopolysaccharide Production, Pilus Expression, and Persistence in the Mouse , 2003, Infection and Immunity.
[4] D. Bassett,et al. Foot lesions associated with Pseudomonas cepacia. , 1971, Lancet.
[5] A. Cox,et al. Structures of the two polymers present in the lipopolysaccharide of Burkholderia (Pseudomonas) cepacia serogroup O4. , 1995, European journal of biochemistry.
[6] D. Woods,et al. Characterization of Pseudomonas cepacia isolates from patients with cystic fibrosis , 1984, Journal of clinical microbiology.
[7] I. Phillips,et al. Pseudomonas cepacia (multivorans) septicaemia in an intensive-care unit. , 1971, Lancet.
[8] A. Cox,et al. Structure of the putative O antigen containing 2-amino-2-deoxy-L-glucose in the reference strain for Pseudomonas cepacia serogroup O1. , 1990, Carbohydrate research.
[9] E. Moxon,et al. Pseudomonas cepacia: an emerging pathogen in chronic granulomatous disease. , 1986, The Journal of pediatrics.
[10] J. Rajyaguru,et al. Association of resistance to trimethoprim/sulphamethoxazole, chloramphenicol and quinolones with changes in major outer membrane proteins and lipopolysaccharide in Burkholderia cepacia. , 1997, The Journal of antimicrobial chemotherapy.
[11] J. Govan,et al. Serum IgG and sputum IgA antibody to core lipopolysaccharide antigen from Pseudomonas cepacia in patients with cystic fibrosis. , 1993, Journal of medical microbiology.
[12] A. Anderson,et al. Structure of the O9 antigen from Burkholderia (Pseudomonas) cepacia. , 1994, FEMS microbiology letters.
[13] W. H. Burkholder. Sour skin, a bacterial rot of Onion bulbs. , 1950 .
[14] D. Woods,et al. 3-deoxy-D-manno-2-octulosonic acid in the lipopolysaccharide of various strains of Pseudomonas cepacia. , 1990, Journal of medical microbiology.
[15] M. Perry,et al. Structure of the lipopolysaccharide O-antigen of Pseudomonas cepacia serotype A. , 1993, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[16] A. Cox,et al. Characterization of a lipopolysaccharide O antigen containing two different trisaccharide repeating units from Burkholderia cepacia serotype E (O2). , 1995, Carbohydrate research.
[17] S. Wilkinson,et al. Lipids and fatty acids of Burkholderia and Ralstonia species , 1999 .
[18] W. Janisiewicz,et al. Biological control of blue mold and gray mold on apple and pear with pseudomonas cepacia , 1988 .
[19] S. Cérantola,et al. Structural studies of the acidic exopolysaccharide produced by a mucoid strain of Burkholderia cepacia, isolated from cystic fibrosis. , 1996, Carbohydrate research.
[20] P. Vandamme,et al. Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. , 2001, International journal of systematic and evolutionary microbiology.
[21] M. Corey,et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. , 1984, The Journal of pediatrics.
[22] J. Govan,et al. Endotoxic activity of lipopolysaccharides isolated from emergent potential cystic fibrosis pathogens. , 2000, FEMS immunology and medical microbiology.
[23] J. Parke. Population dynamics of Pseudomonas cepacia in the pea spermosphere in relation to biocontrol of Pythium. , 1990 .
[24] G. Barclay,et al. Production and characterisation of mouse monoclonal antibodies reactive with the lipopolysaccharide core of Pseudomonas aeruginosa. , 1992, Journal of medical microbiology.
[25] J. Burns,et al. Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance , 1996, Antimicrobial agents and chemotherapy.
[26] H. Heymann,et al. Isolation of atypical lipopolysaccharides from purified cell walls of Pseudomonas cepacia. , 1979, Journal of general microbiology.
[27] Peter Vandamme,et al. Lack of correlation between O-serotype, bacteriophage susceptibility and genomovar status in the Burkholderia cepacia complex. , 2003, FEMS immunology and medical microbiology.
[28] M. Vaara,et al. Characterization of the lipopolysaccharide from the polymyxin‐resistant pmrA mutants of Salmonella typhimurium , 1981, FEBS letters.
[29] D. Woods,et al. Molecular and Physical Characterization of Burkholderia mallei O Antigens , 2002, Journal of bacteriology.
[30] T. Heulin,et al. Polyphasic Taxonomy in the Genus Burkholderia Leading to an Emended Description of the Genus and Proposition of Burkholderia vietnamiensis sp. nov. for N2-Fixing Isolates from Rice in Vietnam , 1995 .
[31] W. Martone,et al. Pseudomonas cepacia typing systems: collaborative study to assess their potential in epidemiologic investigations. , 1989, Reviews of infectious diseases.
[32] T. Coenye,et al. An epidemic Burkholderia cepacia complex strain identified in soil , 2002, The Lancet.
[33] M. Matsuura,et al. Lipopolysaccharide of Burkholderia cepacia and Its Unique Character To Stimulate Murine Macrophages with Relative Lack of Interleukin-1β-Inducing Ability , 2001, Infection and Immunity.
[34] S. Cérantola,et al. Structural elucidation of a novel exopolysaccharide produced by a mucoid clinical isolate of Burkholderia cepacia. Characterization of a trisubstituted glucuronic acid residue in a heptasaccharide repeating unit. , 1999, European journal of biochemistry.
[35] C. Manthey,et al. Elimination of trace endotoxin protein from rough chemotype LPS , 1994 .
[36] A. Cox,et al. Structure of the O-specific polymer for Pseudomonas cepacia serogroup O7. , 1990, Carbohydrate research.
[37] P. Vandamme,et al. Burkholderia cepacia Genomovar III Is a Common Plant-Associated Bacterium , 2001, Applied and Environmental Microbiology.
[38] J. Thomas-Oates,et al. Structural investigation of the lipopolysaccharide from Acinetobacter haemolyticus strain NCTC 10305 (ATCC 17906, DNA group 4). , 1997, European journal of biochemistry.
[39] E. Ligeti,et al. Chronic granulomatous disease: more than the lack of superoxide? , 2001, Journal of leukocyte biology.
[40] A. Cox,et al. Structures of the 0-specific polymers from the LIPOPOLYSACCHARIDES OF THE REFERENCE STRAINS FOR Pseudomonas cepacia SEROGROUPS 03 AND 05 , 1989 .
[41] J. Parke,et al. Zoospore Homing and Infection Events: Effects of the Biocontrol Bacterium Burkholderia cepacia AMMDR1 on Two Oomycete Pathogens of Pea (Pisum sativum L.) , 2000, Applied and Environmental Microbiology.
[42] M. Riley,et al. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain , 1995, Nature Medicine.
[43] A. Chakrabarty,et al. Cloning, physical mapping and expression of chromosomal genes specifying degradation of the herbicide 2,4,5-T by Pseudomonas cepacia AC1100. , 1988, Gene.
[44] C. Whitfield. Biosynthesis of lipopolysaccharide O antigens. , 1995, Trends in microbiology.
[45] R. Stern,et al. Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis , 1990, The Lancet.
[46] I. Kilpeläinen,et al. Lipopolysaccharides of polymyxin B‐resistant mutants of Escherichia coii are extensively substituted by 2‐aminoethyl pyrophosphate and contain aminoarabinose in lipid A , 1995, Molecular microbiology.
[47] J. Leitão,et al. Molecular Typing and Exopolysaccharide Biosynthesis of Burkholderia cepacia Isolates from a Portuguese Cystic Fibrosis Center , 2000, Journal of Clinical Microbiology.
[48] D. Simpson,et al. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis , 1997, Journal of clinical microbiology.
[49] M. Kaufmann,et al. Distribution of Genes Encoding Putative Transmissibility Factors among Epidemic and Nonepidemic Strains ofBurkholderia cepacia from Cystic Fibrosis Patients in the United Kingdom , 2000, Journal of Clinical Microbiology.
[50] S. Gronow,et al. Construction of a Deep-rough Mutant of Burkholderia cepacia ATCC 25416 and Characterization of Its Chemical and Biological Properties* , 2003, The Journal of Biological Chemistry.
[51] J. Matsen,et al. Colonization and infection with Pseudomonas cepacia. , 1972, The Journal of infectious diseases.
[52] P. Vandamme,et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. , 1997, International journal of systematic bacteriology.
[53] Y. Knirel,et al. Antigenic polysaccharides of bacteria , 1974 .
[54] U. Zähringer,et al. Isolation and characterisation of disodium (4-amino-4-deoxy-beta-L- arabinopyranosyl)-(1-->8)-(D-glycero-alpha-D-talo-oct-2-ulopyranosylona te)- (2-->4)-(methyl 3-deoxy-D-manno-oct-2-ulopyranosid)onate from the lipopolysaccharide of Burkholderia cepacia. , 1998, Carbohydrate research.
[55] J. Naismith,et al. The rhamnose pathway. , 2000, Current opinion in structural biology.
[56] Tom Coenye,et al. Taxonomy and Identification of the Burkholderia cepacia Complex , 2001, Journal of Clinical Microbiology.
[57] K. Horiike,et al. Identification and characterization of a new plasmid carrying genes for degradation of 2,4-dichlorophenoxyacetate from Pseudomonas cepacia CSV90 , 1994, Applied and environmental microbiology.
[58] Takayuki Ezaki,et al. Proposal of Burkholderia gen. nov. and Transfer of Seven Species of the Genus Pseudomonas Homology Group II to the New Genus, with the Type Species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. , 1992, Microbiology and immunology.
[59] P. Visca,et al. Phenotypic comparison between rhizosphere and clinical isolates of Burkholderia cepacia. , 1994, Microbiology.
[60] J. Quinn,et al. Pseudomonas cepacia suppression of sunflower wilt fungus and role of antifungal compounds in controlling the disease , 1992, Applied and environmental microbiology.
[61] R. Stern,et al. Pseudomonas cepacia colonization among patients with cystic fibrosis. A new opportunist. , 1985, The American review of respiratory disease.
[62] O. Holst,et al. The structure of the carbohydrate backbone of the lipopolysaccharide from Acinetobacter strain ATCC 17905. , 1997, European journal of biochemistry.
[63] S. Jackson,et al. Lipopolysaccharide (LPS) from Burkholderia cepacia Is More Active than LPS from Pseudomonas aeruginosa and Stenotrophomonas maltophilia in Stimulating Tumor Necrosis Factor Alpha from Human Monocytes , 1999, Infection and Immunity.
[64] V. Deretic,et al. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. , 1996, Microbiological reviews.
[65] E. Yabuuchi,et al. Serological classification of Pseudomonas cepacia by somatic antigen , 1986, Journal of Clinical Microbiology.
[66] R. Hancock,et al. Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance , 1986, Antimicrobial Agents and Chemotherapy.
[67] A. Cox,et al. Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance , 1991, Molecular microbiology.
[68] B. Werneburg,et al. New serotypes of Pseudomonas cepacia. , 1989, Research in microbiology.
[69] D. Woods,et al. Production of an extracellular toxic complex by various strains of Pseudomonas cepacia. , 1989, Journal of medical microbiology.
[70] R. Palfreyman,et al. Induction of biologically active interleukin-8 from lung epithelial cells by Burkholderia (Pseudomonas) cepacia products , 1997, Infection and immunity.
[71] H. Monteil,et al. O and H serotyping of Pseudomonas cepacia , 1983, Journal of clinical microbiology.
[72] J. Govan,et al. Serum sensitivity of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis. , 1994, FEMS immunology and medical microbiology.
[73] S. Wilkinson,et al. Lipopolysaccharide from Burkholderia vietnamiensis strain LMG 6999 contains two polymers identical to those present in the reference strain for Burkholderia cepacia serogroup O4. , 1997, FEMS microbiology letters.
[74] K. Timmis,et al. Degradation of trichloroethylene by Pseudomonas cepacia G4 and the constitutive mutant strain G4 5223 PR1 in aquifer microcosms , 1993, Applied and environmental microbiology.
[75] Richard B. Johnston,et al. Chronic Granulomatous Disease: Report on a National Registry of 368 Patients , 2000, Medicine.
[76] A. Chakrabarty,et al. Plasmid-assisted molecular breeding: new technique for enhanced biodegradation of persistent toxic chemicals. , 1981, Science.
[77] R. Rosselló-Móra,et al. Taxonomic Note: A Pragmatic Approach to the Nomenclature of Phenotypically Similar Genomic Groups , 1995 .
[78] P. Ricciardi-Castagnoli,et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. , 1998, Science.
[79] T. Lessie,et al. Response of Pseudomonas cepacia to beta-Lactam antibiotics: utilization of penicillin G as the carbon source , 1979, Journal of bacteriology.
[80] D. Woods,et al. The importance of extracellular antigens in Pseudomonas cepacia infections. , 1988, Journal of medical microbiology.
[81] P. Vandamme,et al. Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. , 2002, FEMS immunology and medical microbiology.
[82] D. DeShazer,et al. The type II O‐antigenic polysaccharide moiety of Burkholderia pseudomallei lipopolysaccharide is required for serum resistance and virulence , 1998, Molecular microbiology.
[83] G. Keusch,et al. Association of Pseudomonas cepacia with chronic granulomatous disease , 1975, Journal of clinical microbiology.
[84] J. Govan,et al. Lipopolysaccharide chemotypes of Burkholderia cepacia. , 1999, Journal of medical microbiology.
[85] L. Dolzani,et al. Microbiological characterisation of Burkholderia cepacia isolates from cystic fibrosis patients: investigation of the exopolysaccharides produced. , 2002, FEMS microbiology letters.
[86] H. Mayer,et al. Temperature-dependent incorporation of 4-amino-L-arabinose in lipid A of distinct gram-negative bacteria. , 1989, FEMS microbiology letters.
[87] R. Hancock,et al. Role of porins in intrinsic antibiotic resistance of Pseudomonas cepacia , 1987, Antimicrobial Agents and Chemotherapy.
[88] J. Govan,et al. Priming of neutrophil respiratory burst activity by lipopolysaccharide from Burkholderia cepacia , 1997, Infection and immunity.
[89] R. Goldstein,et al. Cable (cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers , 1995, Journal of bacteriology.
[90] P. Vandamme,et al. Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. , 2001, International journal of systematic and evolutionary microbiology.
[91] S. Wilkinson,et al. Structure of the O-specific polysaccharide from Burkholderia vietnamiensis strain LMG 6998. , 1996, Carbohydrate research.
[92] Structural study of the exopolysaccharide produced by a clinical isolate of Burkholderia cepacia. , 2000, Biochemical and biophysical research communications.
[93] J. Lipuma,et al. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. , 2001, American journal of respiratory and critical care medicine.
[94] M. Schell,et al. Characterization of Genes Involved in Biosynthesis of a Novel Antibiotic from Burkholderia cepacia BC11 and Their Role in Biological Control of Rhizoctonia solani , 1998, Applied and Environmental Microbiology.
[95] D. Woods,et al. Development and use of a serotyping scheme for Pseudomonas cepacia , 1987 .
[96] J. Lam,et al. Pseudomonas aeruginosa antigens as potential vaccines. , 1997, FEMS microbiology reviews.
[97] M. Kaufmann,et al. Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. , 1996, Journal of medical microbiology.
[98] M. Dodd,et al. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis , 1993, The Lancet.
[99] A. Linker,et al. The structure of a polysaccharide from infectious strains of Burkholderia cepacia. , 2001, Carbohydrate research.
[100] V. Jonsson. Proposal of a new species Pseudomonas kingii1 , 1970 .
[101] Iu A Knirel',et al. [Immunologic and structural studies of lipopolysaccharides from Pseudomonas cepacia]. , 1989, Mikrobiologicheskii zhurnal.
[102] S. Cérantola,et al. Exopolysaccharide production by mucoid and non-mucoid strains of Burkholderia cepacia. , 2000, FEMS microbiology letters.
[103] A. Wissner,et al. Cystic fibrosis and CFTR , 2001, Pflügers Archiv.
[104] P. de Vos,et al. Identification and Population Structure ofBurkholderia stabilis sp. nov. (formerly Burkholderia cepacia Genomovar IV) , 2000, Journal of Clinical Microbiology.
[105] O. Holst,et al. The core structure of the lipopolysaccharide from the causative agent of plague, Yersinia pestis. , 2002, Carbohydrate research.
[106] R. Cozens,et al. Isolation and characterization of the outer and cytoplasmic membranes of Pseudomonas cepacia. , 1983, Journal of general microbiology.
[107] R. Lehrer,et al. Binding of protegrin-1 to Pseudomonas aeruginosa and Burkholderia cepacia , 2002, Respiratory research.
[108] J. Parke,et al. Diversity of the Burkholderia cepacia complex and implications for risk assessment of biological control strains. , 2001, Annual review of phytopathology.
[109] J. Govan,et al. Biological activity of Burkholderia (Pseudomonas) cepacia lipopolysaccharide. , 1995, FEMS immunology and medical microbiology.
[110] J. Lam,et al. Isolation and characterization of two genes, waaC (rfaC) and waaF (rfaF), involved in Pseudomonas aeruginosa serotype O5 inner-core biosynthesis , 1997, Journal of bacteriology.
[111] A. Prince. Antibiotic resistance of Pseudomonas species. , 1986, The Journal of pediatrics.
[112] O. Lüderitz,et al. Über die Extraktion von Bakterien mit Phenol/Wasser , 1952 .
[113] J. Govan,et al. Pseudomonas cepacia--fatal pulmonary infection in a patient with cystic fibrosis. , 1986, The Journal of infection.
[114] T. Heulin,et al. Repeated beneficial effects of rice inoculation with a strain of Burkholderia vietnamiensison early and late yield components in low fertility sulphate acid soils of Vietnam , 2004, Plant and Soil.
[115] J. Govan,et al. In vitro activities of meropenem, PD 127391, PD 131628, ceftazidime, chloramphenicol, co-trimoxazole, and ciprofloxacin against Pseudomonas cepacia , 1993, Antimicrobial Agents and Chemotherapy.
[116] J. Miller,et al. Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group. , 1994, The Journal of pediatrics.